[New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D002986:Clinical Trials as Topic; D003853:Deoxyribonucleosides / Q000009:adverse effects / Q000627:therapeutic use*; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use; D008134:Long-Term Care; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000099227:Abacavir
D019380:Anti-HIV Agents; D003853:Deoxyribonucleosides; D015224:Dideoxynucleosides; D004338:Drug Combinations; D019259:Lamivudine; D018894:Reverse Transcriptase Inhibitors; C492871:abacavir, lamivudine drug combination; D000099227:Abacavir